用RET重组来治疗非小细胞肺癌
Hui Jing Hoe1, Benjamin J Solomon1,2
1Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Cancer
|April 2, 2025
概括
在非小细胞肺癌 (NSCLC) 中准RET融合已经发展. 选择性抑制剂,如塞尔珀卡提尼布提供卓越的疗效,并建立了对RET融合阳性NSCLC的治疗标准.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 通过突变或融合的异常RET瘤基因激活驱动恶性瘤,包括1-2%的非小细胞肺癌 (NSCLC).
- 早期RET抑制剂在RET融合阳性NSCLC中显示出有限的疗效和显著的毒性.
- 最近的进展包括高度强效和选择性的RET抑制剂,塞尔珀卡提尼布和普拉塞提尼布.
研究的目的:
- 审查RET重组NSCLC的生物学和临床特征.
- 总结一下这种患者群体的治疗策略的演变.
- 讨论抵抗机制和下一代药剂.
主要方法:
- 对RET融合阳性NSCLC研究的文献综述.
- 对选择性RET抑制剂的临床试验数据的分析.
- 检查耐药机制和新兴疗法.
主要成果:
- 塞尔珀卡提尼布和普拉塞提尼布在晚期RET融合阳性NSCLC中表现出高疗效.
- 塞尔珀卡提尼布在未经治疗的患者中显示出对化疗的优越性 (LIBRETTO-431研究).
- 这些药物现在是以前未经治疗的RET融合阳性NSCLC的标准护理.
结论:
- 选择性RET抑制剂在治疗RET融合阳性NSCLC方面取得了重大进展.
- 了解耐药机制对于开发未来的治疗策略至关重要.
- 目前正在进行的研究重点是新型药物,以克服治疗耐药性.
关键词:
在RET的基础上,RET是RET.在 RET NSCLCLC 中.在RET的融合中,RET的融合.RET重新安排的情况.肺癌是一种肺癌.非小细胞肺癌 (NSCLC) 是一种非小细胞肺癌.这种药物是pralsetinib.塞尔珀卡提尼布 (selpercatinib) 是一种可以更多相关视频
10:35A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
Published on: April 5, 2018
10.3K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
The Retinoblastoma Gene
4.0K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.0K
lncRNA - Long Non-coding RNAs
8.4K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
